Functional gastroesophageal reflux disease (GERD) |
| |
Authors: | Kenneth R. DeVault MD Sami R. Achem MD |
| |
Affiliation: | (1) Mayo Clinic Jacksonville, 4500 San Pablo Road, 32224 Jacksonville, FL, USA |
| |
Abstract: | Opinion statement – | Lack of endoscopic esophagitis does not exclude gastroesophageal reflux disease (GERD). | – | Ambulatory pH testing is also an imperfect standard, and patients with both a normal endoscopy and a normal pH test may still have symptoms produced by acid reflux. | – | A therapeutic trial of acid suppression is often the best approach to these patients. | – | Ideally, therapeutic trials should use a medication with a high degree of efficacy in the treatment of GERD to avoid a false-negative test. | – | Proton pump inhibitors (PPIs) are the best currently available medical therapy for all forms of GERD. | – | If the patient does not respond to a once daily PPI, options include increasing the dose of PPIs, and, perhaps, adding another class of agent or studying the patient with an ambulatory pH test. | – | Patients with a negative endoscopy, negative pH test. and those who do not respond to an adequate trial of acid suppression are unlikely to benefit from antireflux surgery. | |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|